Related Articles

News
STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
November 8, 2022
San Francisco Biotechnology Network News
News
Comments Off on STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
“In taking Amgen but not Bristol, the court may have wanted to wade into this complex area one toe at a time,” one expert said. […]

News
STAT+: Four brain-computer interface companies you should watch (other than Neuralink)
July 25, 2022
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Four brain-computer interface companies you should watch (other than Neuralink)
Elon Musk’s Neuralink has been the buzz of Silicon Valley and beyond. But it’s hardly the only company developing “brain-computer interfaces.” […]

News
STAT+: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
January 12, 2023
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
In some of his first public remarks since getting booed on stage last month over Alzheimer’s drug remarks, Regeneron’s George Yancopoulos acknowledged in an interview he could’ve handled things differently. […]